AI Insight
Researchers developed MatchMiner-AI, an open-source artificial intelligence system that matches cancer patients to clinical trials using large language models trained on synthetic electronic health records. The system achieved high precision scores (0.95 for trial-enrolled patients and 0.94 for standard care patients) and provided trial matches for 100% of tested patients compared to 38% coverage by a conventional genomic matching algorithm. When evaluated by oncologists and AI judges, 80% of MatchMiner-AI's trial suggestions were deemed reasonable compared to 53% from the rules-based approach.
Why it matters
This tool could significantly increase clinical trial enrollment rates, which currently stand below 10% for adult cancer patients, by democratizing access to trial matching capabilities. The open-source nature and privacy-preserving design make advanced trial matching accessible to healthcare systems that lack proprietary matching infrastructure.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
-cross
Abstract: Background: Clinical trials are essential to advancing cancer treatments, but fewer than 10% of adults with cancer enroll in therapeutic trials. Open-source AI trial matching tools could democratize access to trial options. Methods: We created MatchMiner-AI, co-developed with practicing clinical oncologists and trained on synthetic electronic health record (EHR) data. It uses open-weight LLMs to summarize patient histories from unstructured EHR text and extract target populations from trial eligibility documents. Embedding and re-ranking models were distilled to retrieve and rank trial and patient suggestions. Multifaceted evaluation was performed, including retrospective quantification of distillation fidelity; applying a closed-source LLM as judge of patient summarization and matching; and evaluation of candidate matches by oncologists. Results: Across retrospective evaluations of distillation fidelity, the pipeline outperformed a baseline text-embedding model, improving mean average precision (MAP) at 20 from 0.44 (95% CI 0.44-0.45) to 0.95 (95% CI 0.95-0.96) for trial-enrolled patients and from 0.38 (95% CI 0.37-0.38) to 0.94 (95% CI 0.93-0.94) for patients who received standard of care therapies. In a 50-patient sample selected for comparison between MatchMiner-AI and a rules-based tumor genomic trial matching algorithm, MatchMiner-AI retrieved trials for all patients, as opposed to 19 patients (38%) who had tumor genomic data available. Among those 19 patients, 80% of 256 trial suggestions retrieved by MatchMiner-AI were deemed reasonable considerations by a frontier LLM, vs 53% of 113 suggestions retrieved by the rules-based approach. Conclusion: MatchMiner-AI is an open-source, open-weights, clinical trial matching AI pipeline for oncology. Synthetic training data, model weights, inference tools, and demonstration frontends are publicly available.